Loading
Quanterix Corp Stock: price and insider trades · United States
1 insider bought €248k of shares over the last 90 days, the latest filed 14 Aug 2026.
Quanterix Corp: what insiders have been doing
Quanterix Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Quanterix Corp logged 97 filings by 13 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 2 purchases totalling €248k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive. At €184k, the purchase published on 14 August 2026 by Donnelly William P is the largest of the period (0.14% of market cap).
With 97 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Since 2021, the database holds 15 purchases and 86 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 138.9 m USD and net income of -107.2 m USD.
The latest purchase dates back some time: it was published 65 days ago, on 14 August 2026. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
384
Thresholds
n/a
Buy Volume
€7M
15 ops. · all time
Sell Volume
€3M
86 ops. · all time
Who traded when
BuySaleWilliam P. Donnelly3 buys
David R. Walt2 buys
Masoud Toloue1 buy
Vandana Sriram1 buy
Since the insiders bought
- -0.2%Entry US$2.92 · Close 16 Oct 2026 US$2.91
- -45.0%Entry US$5.58 · Close at T+365 US$3.07
- -49.8%Entry US$6.17 · Close at T+365 US$3.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Quanterix Corp Hold (neutral), based on 3 analysts. Average price target: US$3.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,194 of 24,158 companies
14.2
score / 100
Value3
Quality25
FCF yld-55%
Earn yld-74%
EV/EBITDA·
ROE-46%
Gross mgn47%
Net mgn-77%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.07
Analyst consensus
3 analystsHold
US$3.00Target US$3.17(+3%)US$3.50
Income statement
RevenueUS$138.7M
Gross profitUS$64.7M47% margin
EBITDA-US$90.9M-66% margin
Net income-US$107.2M-80.2% margin
Valuation
PER (forward)-2.3x
P/Book0.6x
Beta1.01
Balance sheet & cash
Market capUS$145.2M
Total debtUS$37.2M
Free Cash Flow-US$79.8M
Debt / Equity14%
Profitability & ownership
ROE-46.5%
ROA-16.7%
% insiders6.4%
% institutions71.2%
Last declaration on 16 October 2026
Declarations384 total
81 sharesCommon StockSEC:0002120516-26-000018:0
136 sharesCommon StockSEC:0002120516-26-000018:2
135 sharesCommon StockSEC:0002120516-26-000018:4
372 sharesCommon StockSEC:0002120516-26-000018:6
834 sharesCommon StockSEC:0002120516-26-000018:8
25 shares@ US$3.070.0001% mcap1.0% of flowCommon StockSEC:0002120516-26-000018:1
41 shares@ US$3.070.0001% mcap1.7% of flowCommon StockSEC:0002120516-26-000018:3
111 shares@ US$3.070.0002% mcap4.6% of flowCommon StockSEC:0002120516-26-000018:7
249 shares@ US$3.070.0005% mcap10.2% of flowCommon StockSEC:0002120516-26-000018:9
4,224 sharesCommon StockSEC:0001279281-26-000003:0
6,964 shares@ US$3.410.014% mcap1.6% of flowCommon StockSEC:0001207928-26-000011:0
4,398 shares@ US$3.410.0086% mcap57.3% of flowCommon StockSEC:0001515051-26-000005:0
81 sharesCommon StockSEC:0002120516-26-000017:0
136 sharesCommon StockSEC:0002120516-26-000017:2
135 sharesCommon StockSEC:0002120516-26-000017:4
25 shares@ US$2.720.0000% mcap1.1% of flowCommon StockSEC:0002120516-26-000017:1
41 shares@ US$2.720.0001% mcap1.8% of flowCommon StockSEC:0002120516-26-000017:3
372 sharesCommon StockSEC:0002120516-26-000017:6
111 shares@ US$2.720.0002% mcap4.9% of flowCommon StockSEC:0002120516-26-000017:7
834 sharesCommon StockSEC:0002120516-26-000017:8
249 shares@ US$2.720.0004% mcap10.9% of flowCommon StockSEC:0002120516-26-000017:9
159 sharesCommon StockSEC:0002120516-26-000016:0
48 shares@ US$2.670.0001% mcap2.1% of flowCommon StockSEC:0002120516-26-000016:1
3,955 sharesCommon StockSEC:0001689757-26-000005:0
2,802 sharesCommon StockSEC:0001207928-26-000009:0
25 of 384 declarations
About Quanterix Corp
Quanterix Corp. (NASDAQ: QTRX) is a U.S.-based life sciences company headquartered in Billerica, Massachusetts, United States. For international investors, the company sits at the intersection of biomarker science, diagnostics, and translational research. Founded in 2007, Quanterix built its franchise around its proprietary Simoa® platform, which is designed to detect and quantify proteins at extremely low concentrations in blood, serum, plasma, and other biofluids. That ultra-sensitivity is the core of its investment case and the basis of its differentiation versus more conventional measurement technologies. ([quanterix.com](https://www.quanterix.com/about-us/))
Quanterix’s business model is centered on instruments, consumables, assay kits, and related services. Its customer base spans academic research institutions, reference laboratories, biopharma companies, and diagnostic developers. The company’s products include Simoa analyzers and assay kits used in biomarker discovery, clinical research, and emerging diagnostic workflows. Management presents Quanterix as a “discovery-to-diagnostics” platform, with a particularly strong footprint in neurodegenerative disease research, where sensitive biomarker detection is critical for Alzheimer’s and related conditions. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-expands-reach-ivd-and-large-reference-labs))
Read moreShow less
From a competitive standpoint, Quanterix is a specialized technology leader rather than a broad-based diagnostics conglomerate. Its moat comes from technical sensitivity, a meaningful installed base, and a large scientific validation record. The company states that its technology has been supported by more than 3,400 peer-reviewed publications, which helps reinforce credibility in the research community. Geographically, Quanterix sells directly in North America and several European countries, while also reaching customers globally through distribution partners. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-second-quarter-2025))
A key recent strategic development is the 2025 acquisition of Akoya Biosciences, which expanded Quanterix into spatial biology and multiplex tissue imaging with single-cell resolution. The combined platform is intended to connect blood-based and tissue-based biology, broadening Quanterix’s addressable opportunities in neurology, immunology, and oncology. In 2025, the company also highlighted regulatory and commercial progress in markets such as China and South Korea, as well as new collaborations supporting Alzheimer’s testing infrastructure. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-advance?utm_source=openai))
For investors, Quanterix remains a specialized growth story listed on the NASDAQ in the United States, with exposure to research funding cycles and pharmaceutical spending, but with a differentiated platform positioned for precision medicine applications. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-first-quarter-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
